HOUSTON, Nov. 13, 2026 /PRNewswire/ -- AI-designed protein binders require wet-lab validation to confirm their target-binding activity. Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, announced its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The services feature 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data, helping AI-focused life sciences researchers move faster and gain deeper insights.

"3 Hours" and "3 Days"

Sino Biological's XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in just 3 hours, with expression success rates exceeding 99% in established workflows. Supporting the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, the platform accelerates experimental testing of AI-designed protein candidates, enabling faster feedback and design iterations.

Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination for candidate protein. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis.

4 Rapid Screening Services of AI-designed Binders

To support diverse research needs in AI-driven binder discovery, 4RISE™ offers flexible screening and characterization workflows tailored to different candidate formats and validation objectives. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening. Comparative Binder Screening evaluates purified candidates under standardized conditions to support candidate prioritization. Affinity & Kinetic Characterization provides quantitative binding insights for lead selection, while Specialized Binder Expression & Validation supports diverse binder formats through tailored mammalian expression and binding analysis.

Beyond binding, 4RISE™ also provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays, supporting in-depth candidate evaluation and design optimization.

Proven Experience

Sino Biological works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. 4RISE™ wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals.

"AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. "Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications."

Explore 4RISE™ High-Throughput Wet-Lab Validation Services Now!

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sino-biological-launches-4rise-high-throughput-wet-lab-services-to-accelerate-ai-driven-drug-discovery-302938745.html

Images

Tags

More Like This

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies

Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughput Kinase Inhibitor Screening

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

LenioBio partners with AffinityAI to accelerate discovery of novel complex proteins through AI-guided design and high-throughput cell-free expression